Latest Financial Health News

Credit Intelligence Limited has issued a profit warning revealing a reduced loss of approximately A$4.5 million for FY25, down from A$12.5 million the previous year, driven by strategic divestments and a revenue decline.

Iress Limited reported a robust first half of 2025 with strong earnings growth and reduced leverage, driven by core business strength and strategic divestments. The company is poised to capitalize on regulatory tailwinds and technology demand in wealth and trading sectors.

JB Hi-Fi Limited has announced a fully franked dividend of AUD 2.05 per share for the first half of FY2025, combining ordinary and special dividends payable in September.

ResMed Inc. reported a robust 10% increase in revenue to $5.15 billion for fiscal 2025, driven by strong demand in sleep and breathing health devices and residential care software. The company also expanded its diagnostic capabilities with the acquisition of VirtuOx, positioning itself for further growth in home-based health solutions.

Lodestar Minerals launches a pro-rata bonus issue of Loyalty Options to existing shareholders, offering potential future capital without immediate dilution. The options are exercisable at $0.01 until August 2029, aiming to reward long-term investors and support company growth.

SRJ Technologies clarifies its financial position and strategic rationale behind a recent capital raise and acquisition of a UAE entity, addressing ASX concerns over its viability and voluntary suspension.

AMP Limited has announced an ordinary dividend of AUD 0.02 per share for the six months ending June 2025, with a 20% franking credit, payable in late September.

Pinnacle Investment Management announces a fully franked dividend of AUD 0.27 per share for the half-year ending June 2025, offering shareholders a Dividend Reinvestment Plan with currency flexibility.

Trajan Group Holdings has reported record FY25 revenue of $166.5 million, exceeding guidance despite operational headwinds. However, EBITDA fell slightly short of forecasts, reflecting challenges in supply chains and market shifts.

HeraMED Limited has resumed trading on the ASX following the release of its quarterly reports and a significant capital raising announcement, marking a pivotal moment for the medical device company.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.

Hudson Investment Group faces intense scrutiny from ASX after its auditor issued a Disclaimer of Opinion on the 2024 financial report, citing doubts over a $2.4 million property receivable and the company’s going concern status.